The reiteration of a Market Outperform rating and the maintenance of a $12 price target by a reputable analyst like Reni Benjamin from JMP Securities could positively influence investor sentiment towards Werewolf Therapeutics. This endorsement reaffirms the analyst's confidence in the company's potential, likely encouraging both current and potential investors about the stock's future performance.